The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
amyotrophic lateral sclerosis
Rilutek is the first drug shown to provide some benefit to
people with amyotrophic lateral sclerosis. No treatment has
previously been available for this fatal, neurodegenerative disease
since it was first described 126 years ago.
In the largest ALS clinical trial ever, Rilutek was shown to
extend the survival of ALS patients by three months. A total of 959
patients participated in a multicenter, double-blind,
placebo-controlled phase III trial, in which survival served as the
In addition to demonstrating a survival benefit, Rilutek was
generally well tolerated. Side effects reported in the trial
included nausea, fatigue, and elevated liver enzymes.
Advances in Neurology, Vol. 68, Lippincott-Raven Publishers,
The outward signs of ALS are progressive weakness and
deterioration of the muscles (amyotrophic), beginning in the limbs,
usually on one side of the body (lateral). Inside the body, the
nerves controlling motor function die off after their cell bodies
become hardened and shriveled (sclerosis), leaving the patient